CD274 and hepatocellular carcinoma: However, no significant improvement in DCR was found in ICIs treatment in this meta-analysis.<h4>Conclusion</h4>HCC patients would benefit from ICIs treatment, however, more studies are needed in the future to provide more useful evidence for the treatment of HCC by programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors.